Kingsoft Cloud Reports Q4 Revenue of RMB2.761B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy KC?
Reports Q4 revenue RMB2.761B vs. RMB2.232B last year. Tao Zou, CEO of Kingsoft Cloud, commented, "We are very pleased to see another strong quarter to close the FY25. Our record-high financial result is a powerful testament to the confidence our customers place in our products, solutions and services. This quarter our gross billing of AI business achieved a year-over-year growth of 95%, and we continue to see strong intelligent computing demands in 2026. As AI increasingly reshapes industries, we believe we are well-positioned to capture the opportunities in this era."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KC
About KC
Kingsoft Cloud Holdings Ltd is a holding company mainly engaged in independent cloud services. The Company’s modularized cloud products comprise unified IaaS infrastructure, PaaS middleware, SaaS applications, AI capabilities and deployment services, which can be utilized to design different solutions to meet various business needs. The Company’s cloud products primarily consist of cloud computing, storage and delivery. The Company also designs industry-specific solutions covering a wide spectrum of industry verticals, including Internet, public service, healthcare, financial service and enterprise service and others. The Company also offer solutions in a holistic approach, by merging cloud solutions with dedicated customer services. The Company’s end-to-end customer services cover planning, solution development, fulfillment and deployment, as well as ongoing maintenance and upgrade. The Company mainly conducts its businesses in the domestic and overseas market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kingsoft Cloud Reports Record Quarterly Revenue Growth
- Record Revenue Growth: Kingsoft Cloud achieved a quarterly revenue of RMB 2.76 billion, marking a 22% year-over-year increase, which underscores the company's robust performance in the cloud services market and strengthens its competitive position.
- Public Cloud Services Surge: Revenue from public cloud services reached RMB 1.9 billion, a 35% year-over-year growth, reflecting strong demand for intelligent computing services, which is expected to drive future revenue increases.
- AI Business Expansion: The gross billing from the AI business hit RMB 926 million, a staggering 95% year-over-year increase, contributing 49% of public cloud services revenue, indicating the company's rapid expansion and market potential in the AI sector.
- Improved Profitability: The adjusted gross margin stood at 17.1%, with an adjusted operating margin of 2.0%, achieving operational profitability for two consecutive quarters, demonstrating positive progress in cost control and profitability enhancement.
See More
Kingsoft Cloud Q4 Earnings Beat Expectations
- Earnings Performance: Kingsoft Cloud reported a Q4 GAAP EPS of -$0.01, beating market expectations by $0.11, indicating positive signals in the company's recovery of profitability.
- Revenue Growth: The total revenue reached $394.9 million, reflecting a 29.1% year-over-year increase, with public cloud service revenues at RMB 1,902.4 million (approximately $272.0 million), showcasing strong market demand.
- Enterprise Cloud Services: Revenue from enterprise cloud services was RMB 859.0 million (approximately $122.8 million), marking a 4.5% increase from the same quarter in 2024 and an 18.4% rise from the previous quarter, demonstrating sustained demand from enterprise clients for cloud services.
- EBITDA Metrics: Non-GAAP EBITDA stood at RMB 785.2 million (approximately $112.3 million), up 118.3% year-over-year, although it decreased by 5.0% from the previous quarter; however, the EBITDA margin of 28.4% significantly improved from 16.1% in the same quarter of 2024, indicating enhancements in cost control and profitability.
See More
China Rapidly Embraces OpenClaw AI Assistant
- Surge in Market Demand: The usage of OpenClaw in China has surpassed that in the U.S., indicating a strong domestic demand for this open-source AI assistant, which is driving local tech companies to develop related applications and is expected to enhance market competitiveness.
- Tencent Product Launch: Tencent has launched a full suite of AI products based on OpenClaw, dubbed 'Lobster Special Forces,' compatible with its super app WeChat, aiming to attract more users and strengthen its leadership position in the AI market.
- Government Support Policies: Local governments in Shenzhen and Hefei have proposed funding support of up to 10 million yuan to encourage companies to develop applications based on OpenClaw, demonstrating a strong commitment to promoting AI technology development.
- Installation Convenience Improvement: To reduce the installation complexity of OpenClaw, companies like ByteDance and Tencent have introduced simplified versions and on-site installation services, which are expected to attract more non-technical users and further expand the user base.
See More
Kingsoft Cloud to Release Q4 and FY2025 Financial Results
- Earnings Release Schedule: Kingsoft Cloud is set to announce its unaudited financial results for Q4 and FY2025 on March 25, 2025, before the U.S. market opens, which is expected to provide investors with critical performance data to assess the company's future growth potential.
- Conference Call Timing: Management will host an earnings conference call on March 25, 2025, at 8:15 AM U.S. Eastern Time (8:15 PM Beijing/Hong Kong Time), aimed at sharing financial performance and future strategies, thereby enhancing transparency and investor confidence.
- Registration Details: Participants must preregister via a designated link to receive dial-in numbers, event passcodes, and unique access PINs, ensuring a smooth conference experience and improving participant engagement.
- Live Webcast and Archive: The conference will be available via live and archived webcast on the company's investor relations website, allowing investors who cannot attend in real-time to review the meeting content, further enhancing information accessibility and transparency.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Kingsoft Cloud Reports Record Quarterly Revenue Growth
- Record Revenue Growth: Kingsoft Cloud achieved a quarterly revenue of RMB 2.76 billion, marking a 22% year-over-year increase, which underscores the company's robust performance in the cloud services market and strengthens its competitive position.
- Public Cloud Services Surge: Revenue from public cloud services reached RMB 1.9 billion, a 35% year-over-year growth, reflecting strong demand for intelligent computing services, which is expected to drive future revenue increases.
- AI Business Expansion: The gross billing from the AI business hit RMB 926 million, a staggering 95% year-over-year increase, contributing 49% of public cloud services revenue, indicating the company's rapid expansion and market potential in the AI sector.
- Improved Profitability: The adjusted gross margin stood at 17.1%, with an adjusted operating margin of 2.0%, achieving operational profitability for two consecutive quarters, demonstrating positive progress in cost control and profitability enhancement.
See More
Kingsoft Cloud Q4 Earnings Beat Expectations
- Earnings Performance: Kingsoft Cloud reported a Q4 GAAP EPS of -$0.01, beating market expectations by $0.11, indicating positive signals in the company's recovery of profitability.
- Revenue Growth: The total revenue reached $394.9 million, reflecting a 29.1% year-over-year increase, with public cloud service revenues at RMB 1,902.4 million (approximately $272.0 million), showcasing strong market demand.
- Enterprise Cloud Services: Revenue from enterprise cloud services was RMB 859.0 million (approximately $122.8 million), marking a 4.5% increase from the same quarter in 2024 and an 18.4% rise from the previous quarter, demonstrating sustained demand from enterprise clients for cloud services.
- EBITDA Metrics: Non-GAAP EBITDA stood at RMB 785.2 million (approximately $112.3 million), up 118.3% year-over-year, although it decreased by 5.0% from the previous quarter; however, the EBITDA margin of 28.4% significantly improved from 16.1% in the same quarter of 2024, indicating enhancements in cost control and profitability.
See More
China Rapidly Embraces OpenClaw AI Assistant
- Surge in Market Demand: The usage of OpenClaw in China has surpassed that in the U.S., indicating a strong domestic demand for this open-source AI assistant, which is driving local tech companies to develop related applications and is expected to enhance market competitiveness.
- Tencent Product Launch: Tencent has launched a full suite of AI products based on OpenClaw, dubbed 'Lobster Special Forces,' compatible with its super app WeChat, aiming to attract more users and strengthen its leadership position in the AI market.
- Government Support Policies: Local governments in Shenzhen and Hefei have proposed funding support of up to 10 million yuan to encourage companies to develop applications based on OpenClaw, demonstrating a strong commitment to promoting AI technology development.
- Installation Convenience Improvement: To reduce the installation complexity of OpenClaw, companies like ByteDance and Tencent have introduced simplified versions and on-site installation services, which are expected to attract more non-technical users and further expand the user base.
See More
Kingsoft Cloud to Release Q4 and FY2025 Financial Results
- Earnings Release Schedule: Kingsoft Cloud is set to announce its unaudited financial results for Q4 and FY2025 on March 25, 2025, before the U.S. market opens, which is expected to provide investors with critical performance data to assess the company's future growth potential.
- Conference Call Timing: Management will host an earnings conference call on March 25, 2025, at 8:15 AM U.S. Eastern Time (8:15 PM Beijing/Hong Kong Time), aimed at sharing financial performance and future strategies, thereby enhancing transparency and investor confidence.
- Registration Details: Participants must preregister via a designated link to receive dial-in numbers, event passcodes, and unique access PINs, ensuring a smooth conference experience and improving participant engagement.
- Live Webcast and Archive: The conference will be available via live and archived webcast on the company's investor relations website, allowing investors who cannot attend in real-time to review the meeting content, further enhancing information accessibility and transparency.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
